生物化学与生物物理进展
生物化學與生物物理進展
생물화학여생물물리진전
PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS
2003年
3期
335-338
,共4页
张勇%徐静怡%邓巍%张楠%蔡伦%赵义%卜东波%陈润生
張勇%徐靜怡%鄧巍%張楠%蔡倫%趙義%蔔東波%陳潤生
장용%서정이%산외%장남%채륜%조의%복동파%진윤생
SARS冠状病毒%RNA干涉%siRNA%生物信息学
SARS冠狀病毒%RNA榦涉%siRNA%生物信息學
SARS관상병독%RNA간섭%siRNA%생물신식학
SARS coronavirus (SARS-CoV)%RNA interference (RNAi)%small interfering RNA (siRNA)%bioinformatics
RNA干涉(RNA interference, RNAi)是一种特异性地导致转录后基因沉默的现象,在哺乳动物细胞中小分子干扰RNA双链体(small interfering RNA duplexes, siRNA duplexes)可以有效地诱导RNAi现象,为一些疾病的治疗开辟了新的途径.针对SARS冠状病毒(SARS coronavirus, SARS-CoV)中编码5个主要蛋白质的基因,用生物信息学的方法设计了348条候选siRNA靶标.在理论上,相应的siRNA双链体能特异地抑制SARS-CoV靶基因的表达,同时不会影响人体细胞基因的正常表达,这为进一步siRNA类药物的实验研究提供了理论基础.
RNA榦涉(RNA interference, RNAi)是一種特異性地導緻轉錄後基因沉默的現象,在哺乳動物細胞中小分子榦擾RNA雙鏈體(small interfering RNA duplexes, siRNA duplexes)可以有效地誘導RNAi現象,為一些疾病的治療開闢瞭新的途徑.針對SARS冠狀病毒(SARS coronavirus, SARS-CoV)中編碼5箇主要蛋白質的基因,用生物信息學的方法設計瞭348條候選siRNA靶標.在理論上,相應的siRNA雙鏈體能特異地抑製SARS-CoV靶基因的錶達,同時不會影響人體細胞基因的正常錶達,這為進一步siRNA類藥物的實驗研究提供瞭理論基礎.
RNA간섭(RNA interference, RNAi)시일충특이성지도치전록후기인침묵적현상,재포유동물세포중소분자간우RNA쌍련체(small interfering RNA duplexes, siRNA duplexes)가이유효지유도RNAi현상,위일사질병적치료개벽료신적도경.침대SARS관상병독(SARS coronavirus, SARS-CoV)중편마5개주요단백질적기인,용생물신식학적방법설계료348조후선siRNA파표.재이론상,상응적siRNA쌍련체능특이지억제SARS-CoV파기인적표체,동시불회영향인체세포기인적정상표체,저위진일보siRNA류약물적실험연구제공료이론기출.
RNA interference (RNAi) is the process of sequence-specific, post-transcriptional gene silencing in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene. In mammal cells, small interfering RNA (siRNA) duplexes can induce RNAi potently, which may provide a new approach to the therapeutics of certain diseases. Focusing on the five genes which coding five crucial proteins of SARS coronavirus(SARS-CoV) respectively, 348 siRNA candidate targets were obtained following bioinformatic methods. In theory, potent siRNA duplexes specifically suppress expression of their corresponding SARS-CoV target gene, while have no influence on the normal expression of human gene. It would lay a foundation for the further experimental researches on the siRNA-like drug design for the SARS-CoV.